Treating agent and method for activating Smo receptor in ureter primary Cajal cell
By using 500-1000 ng/ml of SAG solution in primary ureteral Cajal cells to activate Smo receptors, the problem of Hedgehog pathway regulation was solved, the activation of the Hedgehog signaling pathway was achieved, and the research and treatment of ureteral dysfunction diseases was promoted.
Patent Information
- Application Number
- CN202411089335.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-09
- Publication Date
- 2024-11-19
AI Technical Summary
The lack of studies on the concentration of Smo receptors in primary Cajal cells of ureters has led to the inability to achieve precise regulation of the Hedgehog pathway, affecting the research and treatment of the etiology of the disease.
500-1000 ng/ml SAG solution is provided as a treatment agent for activating Smo receptors in primary ureteral Cajal cells. The Hedgehog signaling pathway is activated by culturing cells and culturing them in a carbon dioxide incubator for 24-60 hours to determine the maximum SAG The optimal activation concentration is 700-800 ng/ml.
Successfully activate the Hedgehog signaling pathway in primary Cajal cells of ureter, gain insight into the regulatory mechanisms of Smo receptors, provide new therapeutic strategies and personalized medical plans, and promote the diagnosis and treatment of related diseases.
Smart Images

Figure CN118979014A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of pharmaceutical technology, and in particular to a treatment agent and method for activating Smo receptors in primary Cajal cells of the ureter. Background Art
[0002] The ligand of the Hedgehog pathway is the Hh protein, which needs to undergo a series of processing before it becomes active. There are two receptors for the Hedgehog pathway, one is Ptc and the other is Smo. The characteristic of this pathway is that it has an internal feedback regulation mechanism. Under normal circumstances, Smo is a positively activated transcription factor, but the other receptor Ptc can inhibit the activity of the Smo protein, inhibit the downstream pathway, and achieve self-regulation. The transcription factor of the Hedgehog pathway is the Gli protein family, which has several different subtypes, and Gli1 is a common detection target.
[0003] The main receptor of Hh ligand is the transmembrane receptor protein Ptch encoded by the tumor suppressor gene Ptch. Ptch has two homologs in vertebrates, Ptch1 and Ptch2, of which Ptch1 plays the main membrane receptor function and negatively regulates the Hh signaling pathway, while Ptch2 is a complement to Ptch1. Smo is a G protein-coupled receptor 161 (G protein-coupled receptors GPR161) encoded by the proto-oncogene Smoothened, which is responsible for binding to extracellular ligands and initiating intracellular signal transduction.
[0004] Activation of the Hh signaling pathway: When Hh ligand is lacking, Ptch1 located on the cell surface ciliary membrane binds to Smo, preventing Smo from entering the primary cilium, thereby inhibiting the function of Smo and preventing the activation of typical Hh pathway signals; when Hh ligand is sufficient, Hh ligand binds to Ptch1, causing Ptch1 to dissociate from Smo, and Smo is transported to the cilium through lateral transport and phosphorylated, resulting in a conformational change in Smo, thereby regulating protein kinase-dependent Gli hydrolysis and entering the cell nucleus, initiating the transcription and translation of downstream Gli1, Ptch1, and vascular endothelial growth factor coding genes, thereby activating the Hh signaling pathway. The activation process of the Hh signaling pathway is as follows: Figure 1 shown.
[0005] In recent years, the study of Hedgehog pathway activation has attracted much attention. Usually, the Hedgehog pathway is activated by activating the Smo receptor, thereby activating the Hh signaling pathway. However, existing studies have found that different activators, drug concentrations, and drug action time may affect the activation of the pathway.
[0006] Through existing studies, we have found that activating the Hedgehog pathway in primary cajal cells on the ureter may be a new way to explain the cause of certain diseases. However, there is currently a lack of research on the concentration of Smo receptor activators in primary cajal cells on the ureter, which leads to a lack of effective methods to achieve precise regulation of the Hedgehog pathway in these cells.
[0007] Therefore, the present invention aims to solve the technical problem of the concentration of activators of Smo receptors in primary cajal cells on the ureter, and provide new ideas and methods for further studying the regulatory mechanism of the Hedgehog pathway. Through the research of the present invention, we are expected to reveal the activation mechanism of the Hedgehog pathway in primary cajal cells on the ureter, and provide a new targeted method for the etiology of related diseases. Summary of the invention
[0008] The object of the present invention is to provide a treatment agent and method for activating Smo receptors in primary ureteral Cajal cells.
[0009] The present invention solves the technical problem by adopting the following technical solutions:
[0010] In a first aspect, the present invention provides a treatment agent for activating Smo receptors in primary Cajal cells of the ureter, wherein the treatment agent is a 500-1000 ng / ml SAG solution.
[0011] The present invention selects ureteral cajal cells to explore the effect of the Hedgehog signaling pathway on ureteral diseases. In order to explore the effect of the Hedgehog signaling pathway on ureteral diseases, the Hedgehog signaling pathway needs to be activated first. This experiment successfully activated the Hedgehog signaling pathway in ureteral cajal cells by exploring the treatment agent used to activate the Smo receptor in the primary Cajal cells of the ureter.
[0012] SAG is a typical SHH signal agonist, but its activation concentration in cells from different tissues is not the same. This technology is to find out the optimal activation concentration of SAG in primary ureteral cajal cells.
[0013] In one embodiment of the present invention, the treatment agent is a SAG solution with a concentration of 700-800 ng / ml.
[0014] In one embodiment of the present invention, the treatment agent is a SAG solution with a concentration of 720-780 ng / ml.
[0015] In one embodiment of the present invention, the treatment agent is a 750 ng / ml SAG solution.
[0016] In one embodiment of the present invention, the preparation process of the SAG solution is: dissolving SAG in DMSO to form a SAG original solution, and then diluting the SAG original solution with culture medium to 500-1000 ng / ml.
[0017] In one embodiment of the present invention, the preparation process of the SAG solution is: dissolving SAG in DMSO to form a 3-8 mmol / L SAG original solution, and then diluting the SAG original solution with culture medium to a 500-1000 ng / ml SAG solution.
[0018] A second aspect of the present invention provides a method for activating Smo receptors in primary ureteral Cajal cells, comprising the following steps;
[0019] Step 1: Culture ureteral primary Cajal cells to 70% to 80% confluence;
[0020] Step 2: After treatment with SAG solution, culture in a carbon dioxide cell culture incubator for 24 to 60 hours.
[0021] The present invention has the following beneficial effects:
[0022] Deepen the understanding of Cajal cell function: Cajal cells play an important regulatory role in organs such as the digestive tract and urinary system, especially in the peristalsis and urination function of the ureter. By measuring the activation of Smo receptors by SAG and determining its optimal activation concentration, we can have a deeper understanding of the regulatory mechanism of SAG on SMO receptors in primary Cajal cells of the ureter, thereby providing theoretical support for the pathogenesis, diagnosis and treatment of diseases such as ureteral dysfunction, especially ureterectasis.
[0023] Physiological research: Further research can help us better understand the role and regulatory mechanism of SMO receptors in primary Cajal cells of the ureter and promote a deeper understanding of physiological processes such as neural regulation and muscle contraction.
[0024] Disease model and drug screening: Using this experimental result, a more accurate in vitro model of ureteral or urinary system related diseases can be constructed for drug screening and evaluation. By testing the effects of different drugs on Smo receptor activation, new treatment strategies can be discovered or existing treatment options can be optimized.
[0025] Finding new treatments: By understanding the concentration of SAG-activated SMO receptors, new targets and methods can be provided for the treatment of related diseases, such as ureteropelvic junction stenosis, ureteral dysfunction, ureteral dilatation, hydronephrosis and other diseases.
[0026] Personalized medicine: Understanding the optimal activation concentration of Smo receptors in Cajal cells will help achieve personalized treatment. Different individuals may have different responses to Smo receptor activation, so by determining the optimal activation concentration for an individual, a more precise treatment plan can be developed.
[0027] New drug development: This study not only helps us understand the mechanism of action of existing drugs, but may also provide new ideas for the development of new drugs. For example, drugs targeting Smo receptors may have the potential to improve ureteral function or treat related diseases.
[0028] Academic research: The research results can also expand the research on Smo receptors in other organs, promote a deeper understanding of the functions and physiological regulation mechanisms of Smo receptors in other tissues, promote academic research in related fields, promote academic exchanges and cooperation, and promote the development of the entire discipline.
[0029] The experimental results are also expected to provide new ideas for the prevention and diagnosis of ureteral diseases. By activating the SMO receptor, it may be possible to affect the function of ureteral cells, thereby intervening in the early stages of the disease and improving the prevention and diagnosis of the disease. BRIEF DESCRIPTION OF THE DRAWINGS
[0030] Figure 1 Schematic diagram of the activation of the classical Hh signaling pathway in mammalian cells.
[0031] Figure 2 The Smo expression levels are shown in the second group at 50 ng / ml, the third group at 100 ng / ml, the fourth group at 250 ng / ml, and the fifth group at 500 ng / ml.
[0032] Figure 3 The Smo expression in the sixth group at 750 ng / ml and the seventh group at 1000 ng / ml.
[0033] Figure 4 This is the cell morphology of the first group after 48 hours of culture.
[0034] Figure 5 The cell morphology was shown after 48 h of treatment with 750 ng / ml SAG.
[0035] Figure 6 This is the DAPI staining image of the first group of cells after 48 hours of culture, and the blue represents the cell nucleus.
[0036] Figure 7 This is the antibody staining image of the first group of cells after 48 hours of culture, and red represents the target antigen.
[0037] Figure 8 This is the DAPI+ antibody staining image of the first group of cells after 48 hours of culture. The cell nucleus and antigen are in the same photo.
[0038] Fig. 9 This is a DAPI staining image of cells treated with 750 ng / ml SAG for 48 hours, with blue representing cell nuclei.
[0039] Fig.10 This is the antibody staining image of cells treated with SAG at a concentration of 750 ng / ml for 48 hours. The red color represents the target antigen.
[0040] Fig.11 This is a DAPI+ antibody staining image of cells after treatment with 750ng / ml SAG for 48h. The cell nucleus and antigen are in the same photo.
[0041] Unless stated to the contrary, the terms used in the specification and claims have the following meanings.
[0042] As used herein, the term "prevention" refers to preventing the occurrence of a disease and / or preventing the recurrence of a disease. DETAILED DESCRIPTION
[0043] The present invention specification describes the specific implementation scheme in detail. Those skilled in the art should recognize that the following implementation scheme is exemplary and cannot be understood as limiting the present invention. For those skilled in the art, without departing from the principle of the present invention, by making several improvements and modifications to the present invention, the technical solutions obtained by these improvements and modifications also fall within the protection scope of the claims of the present invention. The following examples specifically illustrate the beneficial effects of the present invention.
[0044] Ureteric primary Cajal cell culture protocol
[0045] After pretreatment of the ureteral tissue (rinsing the tissue with saline to remove blood stains), the tissue was chopped up; the chopped tissue was centrifuged to remove the supernatant, and type II collagenase was added and mixed by blowing and digestion. After digestion, the supernatant was discarded. Pancreatic enzyme was added, and the mixture was mixed by blowing and digestion. After digestion, the supernatant was discarded to obtain a cell suspension. The cell suspension was added to the culture medium and resuspended, blown, and transferred into a culture dish and placed in a CO 2 Culture in an incubator for 5-7 days.
[0046] SAG is dissolved in dimethyl sulfoxide (DMSO) to 5 mmol / L, and is further diluted to a corresponding concentration with culture medium when used subsequently. The culture medium is a culture medium for culturing cells, specifically M199 culture medium.
[0047] Example 1
[0048] A method for SAG to activate Smo receptors in primary ureteral Cajal cells, comprising the following steps:
[0049] Step 1: Culture the ureteral primary Cajal cells to 70% to 80% confluence, that is, approximately 70% to 80% of the cells are visible under the microscope.
[0050] Step 2: After treatment with 50 ng / ml of SAG, the cells were cultured in a carbon dioxide cell culture incubator for 48 h, and the expression level of the Smo receptor was determined.
[0051] Example 2
[0052] A method for SAG to activate Smo receptors in primary ureteral Cajal cells, comprising the following steps:
[0053] Step 1: Culture the ureteral primary Cajal cells to 70% to 80% confluence, that is, approximately 70% to 80% of the cells are visible under the microscope.
[0054] Step 2: After treatment with 100 ng / ml of SAG, the cells were cultured in a carbon dioxide cell culture incubator for 48 hours, and the expression level of the Smo receptor was determined.
[0055] Example 3
[0056] A method for SAG to activate Smo receptors in primary ureteral Cajal cells, comprising the following steps:
[0057] Step 1: Culture the ureteral primary Cajal cells to 70% to 80% confluence, that is, approximately 70% to 80% of the cells are visible under the microscope.
[0058] Step 2: After treatment with 250 ng / ml of SAG, the cells were cultured in a carbon dioxide cell culture incubator for 48 h, and the expression level of the Smo receptor was determined.
[0059] Example 4
[0060] A method for SAG to activate Smo receptors in primary ureteral Cajal cells, comprising the following steps:
[0061] Step 1: Culture the ureteral primary Cajal cells to 70% to 80% confluence, that is, approximately 70% to 80% of the cells are visible under the microscope.
[0062] Step 2: After treatment with 500 ng / ml of SAG, the cells were cultured in a carbon dioxide cell culture incubator for 48 hours, and the expression level of the Smo receptor was determined.
[0063] Example 5
[0064] A method for SAG to activate Smo receptors in primary ureteral Cajal cells, comprising the following steps:
[0065] Step 1: Culture the ureteral primary Cajal cells to 70% to 80% confluence, that is, approximately 70% to 80% of the cells are visible under the microscope.
[0066] Step 2: After treatment with 750 ng / ml of SAG, the cells were cultured in a carbon dioxide cell culture incubator for 48 h, and the expression level of the Smo receptor was determined.
[0067] Example 6
[0068] A method for SAG to activate Smo receptors in primary ureteral Cajal cells, comprising the following steps:
[0069] Step 1: Culture the ureteral primary Cajal cells to 70% to 80% confluence, that is, approximately 70% to 80% of the cells are visible under the microscope.
[0070] Step 2: After treatment with 1000 ng / ml of SAG, the cells were cultured in a carbon dioxide cell culture incubator for 48 h, and the expression level of the Smo receptor was determined.
[0071] Example 7
[0072] The optimal activation concentration of Smo receptor in primary ureteral Cajal cells was studied.
[0073] 1. Experimental Grouping
[0074] The cells were divided into 7 groups, each of which was further divided into 3 subgroups, and treated with different concentrations of SAG. The first group was the control group, and the second to seventh groups were treated with different concentrations of SAG (50 ng / ml for the second group, 100 ng / ml for the third group, 250 ng / ml for the fourth group, 500 ng / ml for the fifth group, 750 ng / ml for the sixth group, and 1000 ng / ml for the seventh group).
[0075] 2. Experimental methods
[0076] The second group activated Smo receptor in ureteral primary Cajal cells according to the method of Example 1.
[0077] The third group activated Smo receptor in ureteral primary Cajal cells according to the method of Example 2.
[0078] The fourth group activated the Smo receptor in the ureteral primary Cajal cells according to the method of Example 3.
[0079] The fifth group activated the Smo receptor in the ureteral primary Cajal cells according to the method of Example 4.
[0080] The sixth group activated the Smo receptor in the ureteral primary Cajal cells according to the method of Example 5.
[0081] The seventh group activated the Smo receptor in the ureteral primary Cajal cells according to the method of Example 6.
[0082] 3. Detection method: Use qPCR technology to detect the expression level of Smo receptor.
[0083] Figure 2 The Smo expression levels are shown in the second group at 50 ng / ml, the third group at 100 ng / ml, the fourth group at 250 ng / ml, and the fifth group at 500 ng / ml. Figure 3 The Smo expression in the sixth group at 750 ng / ml and the seventh group at 1000 ng / ml.
[0084] The results showed that the SAG concentration of 500ng / ml to 1000ng / ml showed an upward trend; and under the experimental conditions, SAG treatment at concentrations of 750ng / ml and 1000ng / ml could well activate the Smo receptor in ureteral primary Cajal cells.
[0085] 4. Cell morphology detection after treatment with 750ng / ml SAG
[0086] Figure 4 This is the cell morphology of the first group after 48 hours of culture. Figure 5 The cell morphology was shown after 48 h of treatment with 750 ng / ml SAG.
[0087] As can be seen from the figure, the primary cultured cells conform to the morphology of cajal cells, which are spindle-shaped and have 2 to 3 slender protrusions. At the same time, the cells are connected to each other to form a network. Although the cell morphology did not change much after treatment with 750ng / ml SAG, it was found that most of the cells were smooth muscle cells after staining with a-sma (smooth muscle cell-specific antibody), which reduced the number of cajal cells and increased the number of smooth muscle cells. a-sma is an antibody, and immunofluorescence identification requires antibodies specific to this cell. a-sma is a specific antibody for smooth muscle cells.
[0088] 5. Immunofluorescence detection of cells treated with 750ng / ml SAG
[0089] Immunofluorescence (IF) is based on the reaction principle of antigen and antibody. First, the known antigen or antibody is labeled with fluorescein to make a fluorescent marker, and then the fluorescent antibody (or antigen) is used as a molecular probe to detect the corresponding antigen (or antibody) in cells or tissues. The antigen-antibody complex formed in the cell or tissue contains fluorescein. When the sample is observed under a fluorescence microscope, the fluorescein emits bright fluorescence (yellow-green or orange-red) when irradiated by the excitation light. In this way, the cells or tissues where the fluorescence is located can be observed, so as to qualitatively and locate the antigen or antibody, and quantify it using quantitative technology.
[0090] Both antigen and antibody are α-sma, and they are proteins in nature. Antigen is on the cell, and antibody is artificially added. After antigen and antibody combine, the cytoplasm will appear red under the immunofluorescence microscope. There is no α-sma on cajal cells, so the cytoplasm of cajal cells will not be stained red.
[0091] Figure 6 This is the DAPI staining image of the first group of cells after 48 hours of culture, and the blue represents the cell nucleus. Figure 7 This is the antibody staining image of the first group of cells after 48 hours of culture, and red represents the target antigen. Figure 8 This is the DAPI+ antibody staining image of the first group of cells after 48 hours of culture. The cell nucleus and antigen are in the same photo.
[0092] Fig. 9 This is a DAPI staining image of cells treated with 750 ng / ml SAG for 48 hours, with blue representing cell nuclei. Fig.10 This is the antibody staining image of cells treated with SAG at a concentration of 750 ng / ml for 48 hours. The red color represents the target antigen. Fig.11 This is a DAPI+ antibody staining image of cells after treatment with 750ng / ml SAG for 48h. The cell nucleus and antigen are in the same photo.
[0093] From the results of the immunofluorescence images, we can see that there are not many cells in the first group (control group, without SAG treatment) that have red cytoplasm stained by a-sma, indicating that most cells in the untreated group are cajal cells. However, many smooth muscle cells with red cytoplasm appeared in the 750ng / ml SAG treatment group. This shows that the comparison before and after SAG treatment shows that the appropriate concentration of SAG successfully activates the Hedgehog signaling pathway, reducing cajal cells and increasing smooth muscle cells.
[0094] The specification of the present invention describes the specific implementation scheme in detail. Those skilled in the art should recognize that the above implementation scheme is exemplary and cannot be understood as limiting the present invention. For those skilled in the art, without departing from the principle of the present invention, by making several improvements and modifications to the present invention, the technical solutions obtained by these improvements and modifications also fall within the scope of protection of the claims of the present invention.
Claims
1. A treatment agent for activating Smo receptors in primary ureteral Cajal cells, It is characterized in that The treatment agent is a SAG solution with a concentration of 500-1000 ng / ml.
2. A treatment agent for activating Smo receptors in ureteral primary Cajal cells according to claim 1, It is characterized in that The treatment agent is a SAG solution with a concentration of 700-800 ng / ml.
3. A treatment agent for activating Smo receptors in ureteral primary Cajal cells according to claim 1, It is characterized in that The treatment agent is a SAG solution with a concentration of 720-780 ng / ml.
4. A treatment agent for activating Smo receptors in ureteral primary Cajal cells according to claim 1, It is characterized in that The treatment agent is a 750 ng / ml SAG solution.
5. A solution for activating Smo receptors in primary ureteral Cajal cells according to any one of claims 1 to 4, It is characterized in that The preparation process of the SAG solution is as follows: SAG is dissolved in DMSO to form a SAG original solution, and then the SAG original solution is diluted with culture medium to 500-1000 ng / ml.
6. A solution for activating Smo receptors in primary ureteral Cajal cells according to claim 5, It is characterized in that The preparation process of the SAG solution is as follows: SAG is dissolved in DMSO to form a 3-8 mmol / L SAG original solution, and then the SAG original solution is diluted with culture medium to a 500-1000 ng / ml SAG solution.
7. A method for activating Smo receptors in primary ureteral Cajal cells, comprising the following steps; Step 1: Culture ureteral primary Cajal cells to 70% to 80% confluence; Step 2: After treatment with SAG solution, culture in a carbon dioxide cell culture incubator for 24 to 60 hours.
